Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Deborah Siegal(Population Health Research Institute), Mark Crowther(Population Health Research Institute), Pamela B. Conley(VIR Biotechnology (United States)), Vandana Mathur(Woodside (Australia)), F. Mar(Portola Pharmaceuticals (United States)), Stuart J. Connolly(Population Health Research Institute), Janet M. Leeds(Portola Pharmaceuticals (United States)), Michele Bronson(Portola Pharmaceuticals (United States)), Janice Castillo(Portola Pharmaceuticals (United States)), John T. Curnutte(Portola Pharmaceuticals (United States)), Genmin Lu(Portola Pharmaceuticals (United States)), Alex Gold(Portola Pharmaceuticals (United States)), Brian L. Wiens(Pinnacle Clinical Research)
Cited by 1,040
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Subclinical Atrial Fibrillation and the Risk of Stroke
|New England Journal of Medicine|2012|2.1k
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
|Medicine|2000|1.7k
Canadian Implantable Defibrillator Study (CIDS)
|Circulation|2000|1.6k